Analysis of the Causes of Pharmaceutical Supply Chain Vulnerability and Response Strategies under the Centralised Purchasing Model
DOI:
https://doi.org/10.62051/ijgem.v6n3.06Keywords:
Pharmaceutical supply chain, Supply chain vulnerability, Centralized procurement of drugs, System dynamicsAbstract
With the deepening implementation of the centralized drug procurement policy in China, procurement efficiency has significantly improved, and the economic burden of medication on the public has been alleviated. Meanwhile, the structure and operational environment of the pharmaceutical supply chain have undergone notable changes. This study analyzes the emerging pharmaceutical supply chain structures under the centralized procurement model, summarizes the causes of pharmaceutical supply chain vulnerability based on previous research, and employs a system dynamics causal model to examine the causal relationships and influence pathways among these factors. The study identifies the vulnerability drivers at key nodes, including active pharmaceutical ingredient (API) suppliers, pharmaceutical manufacturers, public healthcare institutions, and retail pharmacies. Finally, it proposes reasonable strategies for enterprises to address pharmaceutical supply chain vulnerability from both preventive and mitigating perspectives.
Downloads
References
[1] Svensson, G. 2000. "A Conceptual Framework for the Analysis of Vulnerability in Supply Chains." International Journal of Physical Distribution & Logistics Management 30 (9): 731-750. https://doi.org/10.1108/09600030010351444
[2] Jüttner U., H. Peck, and M. Christopher. 2003. "Supply Chain Risk Management: Outlining an Agenda for Future Research." International Journal of Logistics: Research and Applications 6 (4): 197-210. https://doi.org/10.1080/13675560310001627016
[3] Ning, Z. 2004. "Influencing Factors and Management Principles of Supply Chain Vulnerability." China Business and Market (4): 15-18. http://doi.org/10.3969/j.issn.1007-8266.2004.04.003
[4] Wagner, S. M., and C. Bode. 2006. "An Empirical Investigation into Supply Chain Vulnerability." Journal of Purchasing and Supply Management 12 (6): 301-312. http://doi.org/10.1016/j.pursup.2007.01.004
[5] Vilko, J., and L. Lättilä. 2018. Analyzing supply chain vulnerability through simulation. Supply Chain Risk Management: Advanced Tools, Models, and Developments, 107-122. https://doi.org/10.1007/978-981-10-4106-8_7
[6] Wang, Y., L. J. Jiao, and W. Jiang. 2021. "Enlightenment from the Driving Factors and Supply Chain of American GPOs in the Past Century from a Deconstruction Perspective." Chinese Health Economics 40 (5): 12-15.
[7] Wong, W. P., P. S. Saw, S. Jomthanachai, L. S. Wang, H. F. Ong, and C. P. Lim. 2023. "Digitalization Enhancement in the Pharmaceutical Supply Network Using a Supply Chain Risk Management Approach." Scientific Reports 13: 22287. http://doi.org/10.1038/s41598-023-49606-z
[8] Silva, J., C. Araujo, and L. Marques. 2020. "Siloed Perceptions in Pharmaceutical Supply Chain Risk Management: A Brazilian Perspective." Latin American Business Review 21 (3): 223-254. http://doi.org/10.1080/10978526.2020.1731315
[9] Zhao, Y., and M. Y. Shi. 2023. "Research on Vulnerability of Medical Device Supply Chain Under Public Health Emergencies." Journal of Beijing Jiaotong University (Social Sciences Edition): 23 (2): 1-12. http://doi.org/10.16797/j.cnki.11-5224/c.20240513.006
[10] Xu, L. J. 2019. "Analysis of Risks and Control Points in Hospital Drug Supply Chain Management." Modern Economic Information (12): 378.
[11] Gupta, H., & Kayande, R. A. 2023. Enhancing pharmaceutical supply chain resilience: A study of pharmaceutical companies in multiple geographies. Indian Journal of Pharmaceutical Education and Research, 57(2), 603-611.
[12] Lawrence, J. M. 2020. "Leveraging a Bayesian Network Approach to Model and Analyze Supplier Vulnerability to Severe Weather Risk: A Case Study of the U.S. Pharmaceutical Supply Chain Following Hurricane Maria." International Journal of Disaster Risk Reduction 48: 101578. https://doi.org/10.1016/j.ijdrr.2020.101607
[13] Sharma, S. K., S. Routroy, R. K. Singh, and U. Nag. 2024. " ." International Journal of Logistics Research and Applications 27 (6): 814-841. http://doi.org/10.1080/13675567.2022.2083590
[14] Gupta, Y. P., and M. Gupta. 1989. "A System Dynamics Model of a JIT Kanban System." Engineering Costs & Production Economics 18 (12): 117-130. https://doi.org/10.1016/0167-188X(89)90030-X
[15] Keilhacker, M. L., and S. Minner. 2017. "Supply Chain Risk Management for Critical Commodities: A System Dynamics Model for the Case of the Rare Earth Elements." Resources, Conservation and Recycling 125: 349-362. https://doi.org/10.1016/j.resconrec.2017.05.004
[16] Aboah, J., M. M. Wilson, K. Bicknell, and K. M. Rich. 2021. Identifying the precursors of vulnerability in agricultural value chains: A system dynamics approach. International Journal of Production Research, 59(3), 683-701. https://doi.org/10.1080/00207543.2019.1704592
[17] Zhou, Y., Z. R. Tang, S. M. Liu, D. Chen, and Q. C. Jiang. 2018. "Research and Discussion on Centralized Drug Procurement Models." Health Economics Research (3): 26-28. http://doi.org/10.3969/j.issn.1672-8106.2024.02.012
[18] Cao, J., Y. Ren, C. Zhao, L. Wang, and F. Fang. 2024. "Analysis and Discussion on the Pharmaceutical Centralized Procurement Implementation—A Case Study of a Large Provincial Hospital in China." Frontiers in Pharmacology 15. http://doi.org/10.3389/fphar.2024.1379595
[19] Xie, M. 2022. "Research on Risk Mitigation Strategies for Pharmaceutical Supply Chain Disruption." Master's Thesis, Southwest Jiaotong University, Chengdu.
[20] Wang, B., P. Liao, X. Y. Tang, Y. Jia, and L. Luo. 2024. "Research on Supply Shortages of Winning Drugs in National Centralized Volume-Based Procurement." Health Economics Research 41 (2): 40-43. http://doi.org/10.14055/j.cnki.33-1056/f.2024.02.013
[21] Moktadir, M. A., S. M. Ali, S. K. Mangla, T. A. Sharmy, S. Luthra, N. Mishra, and J. A. Garza-Reyes, 2018. "Decision Modeling of Risks in Pharmaceutical Supply Chains." Industrial Management & Data Systems 118 (7): 1388-1412. http://doi.org/10.1108/IMDS-10-2017-0465
[22] Fang, Z. J., C. Y. Wang, C. Shen, Y. L. Fan, L. P. Chen, D. Y. Chen, R. Shao and M. L. Shao. 2023. "Current Status, Problems, and Countermeasures of Centralized Procurement of High-Value Medical Consumables." Health Economics Research 40 (9): 23-25+28. http://doi.org/10.14055/j.cnki.33-1056/f.2023.09.015
[23] Li, Y., Y. N. Sheng, M. R. Zhao, and A. Q. Hu. 2017. "Research on Causes and Supply Guarantee of Drug Shortage in China from a Supply Chain Perspective." Health Economics Research (6): 55-59. https://doi.org/10.14055/j.cnki.33-1056/f.20170526.007
[24] Hou, Y. H., and M. Cong. 2011. "Research on Optimization of Medical Supply Chain System Based on GPO." Industrial Technology & Economy 30 (5): 130-134+155. http://doi.org/10.3969/j.issn.1004-910X.2011.05.022
[25] Qiao, Z. L. And Z. Huang. 2022. "Procurement Strategies of Medical Institutions to Deal with Drug Supply Chain Disruption in Volume-based Procurement." Pharmaceutical Journal 41(2): 270-275. http://doi.org/10.3870/j.issn.1004-0781.2022.02.029
[26] Shen, K., C. D. Li, and X. H. Xing. 2009. "Research on Risk Management Model and Application of Pharmaceutical Supply Chain in Transitional China." Journal of Xidian University (Social Science Edition) 19 (3): 98-103. http://doi.org/10.3969/j.issn.1008-472X.2009.03.017
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Global Economics and Management
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
